Boston, United States
ROME Therapeutics, founded in 2020, is pioneering new paths in the biotech sector by targeting the repeatome, a vast, largely unexplored component of the genome. By focusing on this uncharted genetic material, often dismissed as "junk DNA," ROME is opening compelling avenues in the treatment of cancer and autoimmune diseases, offering the potential for revolutionary therapies in these fields.
Since its inception, ROME has identified multiple drug targets and initiated several discovery programs. The early involvement of premier investors like GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund, underscores the startup's strong potential and industry validation. The headquarters in Cambridge, Mass., positions ROME advantageously within a vibrant biotech ecosystem.
Significant recent backing includes an acquisition investment by Pretzel in early 2026, signifying confidence in ROME's strategic direction and the promising application of its scientific discoveries in healthcare.
